王华

一、基本情况

王华教授长期从事多发性骨髓瘤、淋巴瘤等疾病的精准诊疗研究，目前具有近20年的临床经验，在多发性骨髓瘤、淋巴瘤等疾病的复发、治疗耐药及其机制和优化临床治疗方面具有创新性成果，所治疗病患的5年生存率可达国际领先水平。在多发性骨髓瘤、淋巴瘤等疾病个体化治疗和预后判断领域进行了一系列的探索，研究结果被美国NCCN指南引用，在全世界推广应用。多次到美国和欧洲访学交流，采用国际先进诊疗理念结合自身对于疾病独特的理解，对患者进行个体化的风险分层治疗取得令人满意的疗效。主持国家自然基金等多项课题，编写《标准多发性骨髓瘤诊疗学》等专著4部，在国际权威杂志Molecular Cancer、Leukemia、BJC、JHO、Oncologist等发表学术论文40余篇。

周三上午，周五上午越秀，周二、周四上午黄埔

二、学术兼职

中国抗癌协会肿瘤与微生态专委会委员/青委副主委

中国人体健康科技促进会细胞治疗专委会常委

中国人体健康科技促进会浆细胞疾病专委会委员

广东省预防医学会血液肿瘤专委会常委

广东省医药教育协会血液病专委会常委

广州抗癌协会理事/肿瘤复发与转移专委会常委

三、主持科研项目

（1）国家自然基金青年项目（核糖体蛋白S3亚基上调前列腺素内过氧化物合成酶2促进急性白血病发展及其机制研，81700148，已结题）

（2）广东省自然基金（整合素α6靶向纳米多肽的研发及其在急性淋巴细胞白血病中枢浸润治疗中的应用， 2023A1515011862）

（3）广东省自然基金（BCL11A在NK/T细胞淋巴瘤干细胞休眠中的作用与调控机制，2021A1515010093）

（4）广东省自然科学基金-博士启动纵向协同项目（肿瘤微环境IL-1 0/IL-10R通路促进骨髓瘤细胞增殖和化疗耐药及其机制研究，2017A030310193，已结题）

（5）中山大学青年教师培育项目（肿瘤微环境IL-10/IL10R通路促进骨髓瘤细胞增殖和耐药的机制研究No.16ykpy30，已结题）

（6）广东省科技计划项目（白介素-15在NK/T细胞淋巴瘤中过表达及诱导化疗耐药的机制研究，2014A020212577，已结题）

（7）广东省医学科学技术研究基金（白介素15在结外NK/T细胞淋巴瘤中的表达及意义，A2015008，已结题）

（8）中国抗癌协会血液肿瘤科研发展基金（Rd联合克拉霉素方案用于复发难治性多发性骨髓瘤治疗的前瞻性、单臂临床研究）等课题。

四、代表性论著

（1）Wang H#（第一）, Fu BB, Wuxiao ZJ, Li YJ, Huang L, Ma J, Zhai ZM, Guo J, Wu YB, Xu ZS, Feng J, Zhou SS, Chen TT, Chen XG, Li GW, Liu TZ, Huang HB, Zheng RH, Li YH, Tao HF, Zi FM, Wu F, Wang J, Zeng H, Fu CB, Gale RP, Xia ZJ, Liang Y. A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma. Leukemia. 2022 Nov;36(11):2724-2728.（IF:12.9）

（2）Liang D, Wang Q, Zhang W,  Wang Hua#. JAK/STAT in leukemia: a clinical update[J]. Molecular Cancer, 2024, 23(1): 25（IF:36.7）.

（3）Wang H#（第一）, Fu BB, Gale RP, Liang Y. NK-/T-cell lymphomas. Leukemia. 2021 Sep;35(9):2460-2468. （IF:12.9）

（4）Zhang W, Li Y, Chen G, Yang X, Hu J, Zhang X, Wang H*（通讯）. Integrin α6-Targeted Molecular Imaging of Central Nervous System Leukemia in Mice. Frontiers in Bioengineering and Biotechnology. 2022;10. （IF:6.06）

（5）Bai S, Wang H, Shao R, Fu B, Lu S, Wang J, Lu Y, Wang H*（通讯）. Lipid profile as a novel prognostic predictor for patients with acute myeloid leukemia. Front Oncol. 2023 Jan 31;13:950732. （IF:5.74）

（6）Fu B, Shao R, Wang H, Chen G, Bai S, Wang H*（通讯）. Integrated assessment of the clinical and biological value of ferroptosis-related genes in multiple myeloma. Cancer Cell Int. 2022 Oct 23;22(1):326. （IF:6.4）

（7）He R, Wen W, Fu B, Zhu R, Chen G, Bai S, Cao X, Wang H*（通讯）. CircKIF4A Is a Prognostic Factor and Modulator of Natural Killer/T-Cell Lymphoma Progression. Cancers (Basel). 2022 Oct 9;14(19):4950. （IF:6.58）

（8）Chen GJ, Wuxiao ZJ, Liang Y, Li C, Fu BB, Wang H*（通讯）. Inflammation-based Glasgow prognostic score as an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. Chin Med J (Engl) . 2021 Jan 15;134(5):579-581. （IF:6.13）

（9）Wang H#（第一）, Wang L, Li C, Wuxiao Z, Shao R, Wang H, Lu Y. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study. Oncologist. 2020 Nov;25(11):e1663-e1670. （IF:5.84）

（10）Wang Y, Wang H#（共一）, Wang W, Liu W, Liu N, Liu S, Lu Y. Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients. BMC Cancer. 2020 Aug 5;20(1):732. （IF:4.64）

（11）Li C, Wuxiao ZJ, Chen X, Chen G, Lu Y, Xia Z, Liang Y, Wang H*（通讯）. A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience. Cancer Res Treat. 2020 Apr;52(2):573-585. （IF:5.04）

（12）Wang H#（第一）, Wang L, Li C, Wuxiao Z, Chen G, Luo W, Lu Y. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. Oncologist. 2020 Nov;25(11):e1725-e1731. （IF:5.84）

（13）Shi H, Li C, Feng W, Yue J, Song J, Peng A, Wang H*（通讯）. BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer/T-Cell Lymphoma. Front Pharmacol. 2020 Jun 4;11:820. （IF:5.99）

（14）Li C, Cai X, Chen X, Liang Y, Xia Z, Wang H*（通讯）. Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. Int J Hematol. 2019 Oct;110(4):458-465. （IF:2.32）

（15）Wang H#（第一）, Hu WM, Xia ZJ, Liang Y, Lu Y, Lin SX, Tang H. High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. J Cancer. 2019 Jun 2;10(14):3239-3245. （IF:4.48）

(15)Hua Wang, Liang Wang,Pei-dong Chi,et al.High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.British Journal of Cancer (2016) 114, 463–468.(影响因子5.569)

(16)Hua Wang, Liang Wang, Wen-Jian Liu,et al.High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.Oncotarget.2016May31;7(22):33035-45(影响因子5.008).

(17)Hua Wang, Pengfei Li, Liang Wang,et al.High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type.Ann Hematol.2015 Sep;94(9):1535-44. (影响因子3.022).

(18) Hua Wang, Zhi-Jun Wuxiao, Jiayu Zhu,et al.Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study. Leukemia & Lymphoma2015; 56(4): 971–977 . (影响因子3.093)

(19) Hua Wang, Jia-yu Zhu，Cheng-cheng Liu,et al. Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma. Med Oncol (2015)32:370. (影响因子2.486)

(20)Hua Wang,Liang Wang,Yue Lu,et al.Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.OncoTargets and Therapy 2016:9 587–595 (影响因子2.272)

(21)Hua Wang, Liang Wang, Zhijun Wuxiao,et al.Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy.Onco Targets Ther. 2015 Sep 14;8:2589-99. (影响因子2.272)

(22)Hua Wang, Pengfei Li, XinKe Zhang,et al.Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.Oncology Letters 2016;12: 825-836. (影响因子1.482)

(23)Meng-yuan Zhu, Hua Wang*(通讯作者), Chun-yu Huang,et al.A childhood chemotherapy protocol improves overall survival among adults with T- lymphoblastic lymphoma.Oncotarget. 2016 Jun 21;7(25):38884-38891.. (影响因子5.008).

(24)Pengfei Li, Li Jiang, Xinke Zhang, Jun Liu, Hua Wang*(通讯作者).CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.BMC Cancer 2014, 14:890. (影响因子3.362).

(25)Jiayu Zhu, Hua Wang*(通讯作者), Cheng‑Cheng Li,et al.The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. J Cancer Res Clin Oncol. 2016 Nov;142(11):2339-45. (影响因子3.141)

(26)Xi-wen Bi, Hua Wang(共同第一), Wen-wen Zhang,et al.PD-L1 is upregulated by EBV-driven LMP1through NF-κB pathway and correlates withpoor prognosis in natural killer/T-cellLymphoma.Journal of Hematology & Oncology (2016) 9:109. (影响因子6.263).

(27)Cheng-cheng Liu, Hua Wang (共同第一), Jing-hua Wang，et al.Serum neuron-specific enolase levels are upregulated inpatients with acute lymphoblastic leukemia and are predictiveof prognosis.Oncotarget. 2016 Jul 7. (影响因子5.008)

(28)Jing-hua Wang, Hua Wang(共同第一), Yan-jun Wang,et al.Analysis of the efficacy and safety of a combinedgemcitabine,oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.Oncotarget. 2016Jun7;7(23):35412-22. (影响因子5.008)

(29)Liang Wang , Hua Wang (共同第一), Chen H, et al.Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.Oncotarget. 2015 ;6(38):41228-36. (影响因子5.008)

(30)Liang Wang , Hua Wang(共同第一), Jinghua Wang,et al.

Post-treatment plasma EBV-DNA positivity predicts early

relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.Oncotarget. 2015;6(30):30317-26. (影响因子5.008)

(31)Liang Wang ,Hua Wang, (共同第一) Pengfei Li, et al.CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type.Ann Hematol. 2015 Aug;94(8):1381-8. (影响因子3.022).

(32)Liang Wang, Hua Wang(共同第一) ,Zhongjun Xia,et al.Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma.Ann Hematol. 2015 Oct;94(10):1645-54. (影响因子3.022).

(33)Cheng-cheng Liu,Hua Wang (共同第一),Wei-da Wang ,et al. Consolidation therapy of arsenic trioxidealternated with chemotherapy achievesremarkable efficacy in newly diagnosedacute promyelocytic leukemia.OncoTargets and Therapy 2015:8 3297–3303.

 (影响因子2.272)

(34)Si Wei Li, Hua Wang (共同第一),Mei lian Liu,et al.Positive effect of high RKIP expression on reduced distantmetastasis by chemotherapy when combined with radiotherapyin locoregionally advanced nasopharyngeal carcinoma:a prospective study.Med Oncol (2013) 30:322. (影响因子2.058)